Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis-Reference-Cited by-同舟云学术

Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis

Published:2024-03 Issue: Volume: Page:
ISSN:0039-6257
Container-title:Survey of Ophthalmology
language:en
Short-container-title:Survey of Ophthalmology

Author:

Ortiz-Seller Amparo,Martorell Pablo,Barranco Honorio,Pascual-Camps Isabel,Morcillo Esteban,Ortiz José L.

Funder

Universitat de València

INCLIVA Instituto de Investigación Sanitaria

Publisher

Elsevier BV

Reference126 articles.

1. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab;Avery;Retina,2017

2. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity;Bai;Br J Ophthalmol,2019

3. Update in the Treatment of Retinopathy of Prematurity;Bancalari;Am J Perinatol,2022

4. New trends in intravitreal anti-VEGF therapy for ROP;Beccasio;Eur J Ophthalmol,2022

5. Bevacizumab or laser for aggressive posterior retinopathy of prematurity;Blair;Taiwan J Ophthalmol,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Different Doses of Oral and Ocular Propranolol for Retinopathy of Prematurity: A Network Meta-Analysis;Pediatric Drugs;2024-08-07

2. Reduction of pathological retinal neovascularization, vessel obliteration, and artery tortuosity by PEDF protein in an oxygen‐induced ischemic retinopathy rat model;FASEB BioAdvances;2024-07-19

3. ROP: 80 Years after Its Detection – Where Do We Stand and How Long Will We Continue to Laser?;Neonatology;2024-05-22